<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01562938</url>
  </required_header>
  <id_info>
    <org_study_id>CD-ID-MEDI-557-1092</org_study_id>
    <nct_id>NCT01562938</nct_id>
  </id_info>
  <brief_title>MEDI-557 Adult Dosing</brief_title>
  <acronym>CD-1092</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of MEDI-557, a Humanized Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus (RSV), Administered to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, double-blind, placebo controlled study enrolling 42 healthy adult subjects&#xD;
      (18-45yrs) from 1 site. Subjects will be randomized in a 2:3:2 ratio to receive MEDI-557 or&#xD;
      placebo. Subjects will receive 1 intravenous dose on Study Day 1. Subjects will be followed&#xD;
      for safety from the time of Informed Consent through 360 days post dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, randomized, double-blind, placebo-controlled study evaluating the safety and&#xD;
      tolerability of MEDI-557 administered IV to healthy adult subjects (18-45yrs). A maximum of&#xD;
      42 subjects from 1 site will be enrolled in a 2:3:2 ratio (12 placebo, 18 MEDI-557 low-dose,&#xD;
      12 MEDI-557 high-dose) to allow for greater data collection in the low-dose group. Subjects&#xD;
      are evaluated for safety from time of Informed Consent through Study Day 360 post dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>from time of informed consent through 360 days post dose (approximately 1 year total)</time_frame>
    <description>The occurrence of AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Pre-dose; every 30 minutes during infusion; up to 24 hours after end of infusion</time_frame>
    <description>Vital sign measurements - blood pressure, heart rate, respiratory rate, temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>from Day 1 (pre-dose) through 360 days post dose.</time_frame>
    <description>Clinical lab measurements - chemistry, hematology; Urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessments - Serum</measure>
    <time_frame>1st dose through 360 days post dose</time_frame>
    <description>Maximum serum concentration; Time to maximum serum concentration; Terminal phase elimination half-life; Area under the serum concentration-time curve from time zero to last measurable time point; Area under the serum concentration-time curve from time zero to infinity; Clearance; Volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-MEDI-557 antibody - Serum and Nasal Wash</measure>
    <time_frame>1st dose through 360 days post dose</time_frame>
    <description>MEDI-557 concentrations in serum and nasal wash through 360 days post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessments - Nasal Wash</measure>
    <time_frame>1st dose through 360 days post dose</time_frame>
    <description>Maximum nasal wash concentration; Time to maximum nasal wash concentration; Area under the nasal wash conentration-time curve from time zero to last measurable time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-RSV antibody in Serum and Nasal Wash</measure>
    <time_frame>1st dose through 360 days post dose</time_frame>
    <description>To evaluate anti-RSV antibodies (F-specific IgG and neutralizing) in serum and nasal wash.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-557 low-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-557 high-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-557</intervention_name>
    <description>MEDI-557 low-dose</description>
    <arm_group_label>MEDI-557 low-dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-557</intervention_name>
    <description>MEDI-557 high-dose</description>
    <arm_group_label>MEDI-557 high-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-45 years&#xD;
&#xD;
          -  written informed consent obtained from subject prior to performing any protocol&#xD;
             related procedures&#xD;
&#xD;
          -  healthy by medical history and physical exam&#xD;
&#xD;
          -  females of child-bearing potential must use 2 effective methods of birth control for&#xD;
             14 days prior to 1st dose and through 1 year after administration of study drug&#xD;
&#xD;
          -  nonsterilized, sexually active males with female partner of child-bearing potential&#xD;
             must use 2 effective methods of birth control from Day 1 through Day 361&#xD;
&#xD;
          -  weight &lt;/= 110kg with a body mass index of &lt;32kg/m2&#xD;
&#xD;
          -  ability to complete a follow-up period of approximately 360 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to complete a follow-up period of 360 days&#xD;
&#xD;
          -  any condition in the opinion of investigator that would interfere with evaluation of&#xD;
             IP or interpretation of subject safety or study results&#xD;
&#xD;
          -  concurrent enrollment in another clinical study&#xD;
&#xD;
          -  employees of the site or other individuals involved with the conduct of the study or&#xD;
             immediate family members of such individuals&#xD;
&#xD;
          -  receipt of immunoglobulin or blood products within 60 days prior to randomziation&#xD;
&#xD;
          -  receipt of any investigational drug therapy within 6 months prior to IP dosing&#xD;
&#xD;
          -  clinically abnormal ECG at screening&#xD;
&#xD;
          -  blood donation in excess of 400mL, wihtin 6 months prior to randomization&#xD;
&#xD;
          -  previous receipt fo biologics&#xD;
&#xD;
          -  history of immunodeficiency&#xD;
&#xD;
          -  history of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the IP&#xD;
&#xD;
          -  previous medical history or evidence of interurrent illness that may compromise the&#xD;
             safety of the subject&#xD;
&#xD;
          -  positive lab test for Hep A, B, C or HIV&#xD;
&#xD;
          -  pregnancy or nursing mother&#xD;
&#xD;
          -  history of alcohol or drug abuse within past 2 years&#xD;
&#xD;
          -  positive urine Class A drug screen&#xD;
&#xD;
          -  acute illness within 7 days prior to randomization&#xD;
&#xD;
          -  fever &gt;/= 99.5F witin 7 days prior to randomization&#xD;
&#xD;
          -  any drug therapy within 7 days prior to randomization&#xD;
&#xD;
          -  systolic BP &gt;150mmHG and/or diastolic BP&gt;90mmHg&#xD;
&#xD;
          -  receipt of vaccine within 14 days prior to randomization&#xD;
&#xD;
          -  abnormal study labs (hem/wbc/platelet/BUN - see protocol for specific information)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Feldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan Jafri</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <last_update_submitted>October 4, 2013</last_update_submitted>
  <last_update_submitted_qc>October 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

